Maryam Henein is a native of Montreal, Canada and is a self-proclaimed health expert.  She is infamous for writing a book about the so-called “disappearing bees” folklore.  She has recently appeared along with “Hollywood film maker” Jason Goodman on the conspiracy brand CrowdSource The Truth podcast.  Now the U.S. Food and Drug Administration has some questions for the alleged “bee lady”.



Above:  “Hollywood film maker” Jason Goodman interviews Maryam Henein on his conspiracy theory show



Apparently the FDA takes issue with some of the claims made by Ms. Henien’s alleged web-site operated under the company name “Honey Colony”.



Date:               May 4, 2020

RE:                 Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address, http://www.honeycolony.com, on April 22, 2020, and on April 30, 2020, respectively. We also reviewed your social media websites at http://www.instagram.com/honeycolonyofficial and http://www.twitter.com/Honeycolony, where you direct consumers to your website, http://www.honeycolony.com, to purchase your products. The FDA has observed that your website offers the products “Quicksilver Liposomal Vitamin C w/ Liposomal,” “Jigsaw Magnesium With SRT,” and products labeled to contain silver, including “Silver Excelsior Serum” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).


Above:  Alleged products that concern the FDA


You should take immediate action to correct the violations cited in this letter.  This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations.  It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA’s implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act.  Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to correct these violations.  Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.  Failure to immediately correct the violations cited in this letter may result in legal action, including, without limitation, seizure and injunction.

In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.  For COVID-19, no such study is currently known to exist for the products identified above.  Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence.  You must immediately cease making all such claims.  Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088



Federal regulators have sent a warning letter to the website HoneyColony after it promoted its products as a way to “mitigate, prevent, treat, diagnose, or cure COVID-19 in people.” The action comes after Media Matters reported on the company, whose site and founder have also frequently pushed dangerous conspiracy theories.

HoneyColony is a California-based company which describes itself as “an online magazine and eccommerce site that empowers you to be your own best health advocate.” Its Facebook page has over 100,000 followers, while its Instagram page has over 11,000 followers.

On May 4, the Food and Drug Administration and the Federal Trade Commission sent a letter to the company stating that it found that HoneyColony was selling products that “are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act.” The letter then noted numerous claims on HoneyColony’s website that “establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19.”

HoneyColony is led by writer and conspiracy theorist Maryam Henein. During the pandemic, she has spread coronavirus lies, including linking 5G to the coronavirus; claiming that the pandemic is “a smokescreen to instill more control, vaccine mandates, a globalist world”; and pushing the empty hospitals conspiracy theory.


To be continued….



FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of criminal justice, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a fair use of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond fair use, you must obtain permission from the copyright owner.


Copyright 2020